

The background of the left side of the page is a photograph of the Duke University Chapel tower, a tall, ornate Gothic-style stone structure with multiple spires and arched windows, set against a clear blue sky.

STATEMENT OF NEED:

The objective of the one-day symposium is to provide practitioners with the latest information on therapies for the most common liver diseases. The program will feature expert speakers who will discuss new treatments for patients with HCV, diagnostic and management strategies for liver cancer, and updates in HBV, NAFLD, hepatic encephalopathy and liver transplantation.

LEARNING OBJECTIVES:

At the conclusion of this activity, participants should be able to:

1. Review and discuss the management of care of patients with hepatitis B&C
2. Identify indications for liver transplantation
3. Describe the management of care of patients with non-alcoholic fatty liver disease

TARGET AUDIENCE:

The target audience for this activity includes physicians and other providers in gastroenterology, hepatology, infectious diseases and internal medicine who have an interest in caring for patients with liver disease.

REGISTRATION: 7:45–8:15 AM

SYMPOSIUM: 8:15 AM–3:00 PM

\$75: Physicians

\$25: Nurses and other non-MDs

FREE: Residents, fellows, and trainees

Fee includes all materials, breaks, and lunch.

Due to planning requirements, fees are

non refundable. ***Pre-registration deadline***

is Thursday, September 12, 2013. On-site registrations are subject to space limitations.

REGISTER ONLINE

<http://cmetracker.net/DUKE/login?FormName=RegLoginLive&Eventid=48146>

DIRECTIONS:

<https://www.dcri.org/about-us/address>

ACCREDITATION

The Duke University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

The Duke University School of Medicine designates this live activity for a maximum of **5.0 AMA PRA Category 1 Credit(s)TM**.

Physicians should only claim credit commensurate with the extent of their participation in the activity.

The American Nurses Credentialing Centers on Accreditation has approved a maximum of **5.0 CEU credits**. Nurses should only claim credit commensurate with the extent of their participation in the activity.

DISCLOSURE

The Duke University School of Medicine adheres to ACCME Essential Areas, Standards, and Policies regarding industry support of continuing medical education. Disclosure of the planning committee and faculty's commercial relationships will be made known at the activity. Speakers are required to openly disclose any limitations of data and/or any discussion of any off-label, experimental, or investigational uses of drugs or devices in their presentations.

RESOLUTION OF CONFLICTS OF INTEREST

In accordance with the ACCME Standards for Commercial Support of CME, the Duke University School of Medicine will implement mechanisms, prior to the planning and implementation of this CME activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME activity.

DISCLAIMER

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.


COMMERCIAL SUPPORT ACKNOWLEDGMENT

This CME activity is supported by educational grants. A complete list of supporters will be published in the course syllabus.

The Duke Department of Medicine presents
**The Duke Liver Disease
Update and Symposium**

Saturday, September 21, 2013
North Pavilion, Duke Clinical Research
Institute

Sponsored by
Duke University School of Medicine



PROGRAM DIRECTORS



ANDREW J. MUIR, MD
Associate Professor of Medicine
Director, GI/Hepatology Research
Duke Clinical Research Institute

Dr. Muir is the Director of the Gastroenterology/Hepatology Research Program at the DCRI. He specializes in general and transplant hepatology, and his research interests include hepatitis C, liver transplantation, clinical trials, racial disparities in liver disease, and outcomes research. He also serves as the Clinical Director of Hepatology and the Gastroenterology Fellowship Director.


After receiving his MD from the Duke University School of Medicine in 1993, Dr. Muir completed his residency in internal medicine and fellowship in gastroenterology at Duke University Medical Center. He also served as Chief Resident in internal medicine.



CARL BERG, MD
Professor of Medicine
Division of Gastroenterology
Department of Medicine
Duke University Medical Center

Dr. Berg is the Medical Director of Abdominal Transplantation at Duke and a Transplant Hepatologist. He specializes in general and transplant hepatology, and his clinical interests include liver transplantation, novel approaches to transplantation, metabolic liver disease, and outcomes research. He is an internationally recognized transplant physician and is currently President-elect of the United Network for Organ Sharing (UNOS).

After receiving his MD from the Washington University School of Medicine in 1986, Dr. Berg remained at Washington University and completed his residency in Internal Medicine at Barnes Hospital. He completed his GI and Hepatology fellowship training at Brigham and Women's Hospital and Harvard in 1992. Prior to his recruitment to Duke in 2012, he was the David D. Stone Endowed Professor of Medicine and Chief of Gastroenterology and Hepatology at the University of Virginia.



ALASTAIR D. SMITH, MB, CHB
Medical Director of Liver Transplantation
Associate Clinical Professor of Medicine
Division of Gastroenterology
Department of Medicine
Duke University Medical Center

Dr. Smith graduated in physiology and then medicine from Aberdeen University, UK. He completed postgraduate training in general medicine, gastroenterology and liver disease in Aberdeen, Liverpool and Glasgow. Upon his arrival at Duke University in 1997, he undertook laboratory research followed by clinical training in advanced liver disease before accepting a junior faculty appointment. He returned to the UK during October 1999 as a consultant physician and gastroenterologist at Eastbourne District General Hospital. He returned to Duke during 2003 to his current position. He was elected a fellow of the Royal College Physicians of Glasgow in 2004.

His clinical interests encompass all aspects of end-stage liver disease and its complications, liver transplantation, management of immunosuppressive drug therapy and recurrent liver disease. He also has a particular interest in autoimmune hepatitis and primary sclerosing cholangitis.

INVITED SPEAKER



ADRIAN M. DI BISCEGLIE, MD, FACP
Badeeh A. & Catherine V. Bander,
Chair in Internal Medicine
Chairman and Professor of Internal Medicine
Chief of Hepatology
Saint Louis University School of Medicine

Program

Time	Topic	Speakers
7:45am - 8:15am	Registration/Breakfast	
8:15am - 8:30am	Welcome	Dr. Andrew J. Muir, DUMC
8:30am - 9:15am	Nonalcoholic Fatty Liver Disease	Dr. Anna Mae Diehl, DUMC
9:15am - 10:00am	Hepatitis C	Dr. Andrew J. Muir, DUMC
10:00am - 10:30am	Break/Exhibits	
10:30am - 11:15am	Hepatocellular Carcinoma	Dr. Adrian Di Bisceglie, St. Louis School of Medicine
11:15am - 12:00pm	Hepatic Encephalopathy	Dr. Alastair Smith, DUMC
12:00pm - 1:00pm	Lunch & Exhibits	
1:00pm - 1:45pm	Liver Transplantation	Dr. Carl Berg, DUMC
1:45pm - 2:30pm	Hepatitis B	Dr. Keyur Patel, DUMC
2:30pm - 3:00pm	Panel Discussion	
3:00pm	Meeting adjourns	

Please note: Faculty and program are subject to change without notice.
Opportunities for Q&A will be provided at the conclusion of each presentation.

HOTEL ACCOMMODATIONS

Washington Duke Inn & Golf Club
3001 Cameron Boulevard
Durham, NC 27705
1-800-443-3853

Millennium Hotel
2800 Campus Walk Avenue
Durham, NC 27705
919-383-8575

Hilton Durham
3800 Hillsborough Road
Durham, NC 27705
919-383-8033

For More Information Contact:

Lou Ann Mitchell: 919-668-7193
email: louann.mitchell@duke.edu